Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
Palisade Bio (NASDAQ: PALI) announced that two abstracts featuring its lead program PALI-2108 for ulcerative colitis treatment have been selected for presentation at Digestive Disease Week (DDW) 2025, scheduled for May 3-6 in San Diego.
The first presentation, focusing on bioinformatic approaches to PALI-2108 treatment in ulcerative colitis, will explore anti-fibrotic efficacy potential with local PDE4 inhibition in intestinal fibrosis. This session is scheduled for May 4, 2025.
The second abstract, recognized as a Poster of Distinction and rated in the top 10% of all AGA abstracts, will present findings on PALI-2108's colon-specific PDE4 inhibitor prodrug properties. The research demonstrates the drug's bioactivation in the colon, its dose-dependent reduction of colon tissue PDE4B, increased c-AMP, and TNF-α suppression in a mouse colitis model. This presentation is scheduled for May 5, 2025.
Palisade Bio (NASDAQ: PALI) ha annunciato che due abstract riguardanti il suo programma principale PALI-2108 per il trattamento della colite ulcerosa sono stati selezionati per la presentazione alla Digestive Disease Week (DDW) 2025, in programma dal 3 al 6 maggio a San Diego.
La prima presentazione, che si concentra sugli approcci bioinformatici al trattamento con PALI-2108 nella colite ulcerosa, esplorerà il potenziale di efficacia anti-fibrotica con l'inibizione locale della PDE4 nella fibrosi intestinale. Questa sessione è programmata per il 4 maggio 2025.
Il secondo abstract, riconosciuto come Poster of Distinction e classificato tra il 10% migliore di tutti gli abstract AGA, presenterà i risultati sulle proprietà del pro-farmaco inibitore della PDE4 specifico per il colon di PALI-2108. La ricerca dimostra la bioattivazione del farmaco nel colon, la riduzione dose-dipendente della PDE4B nei tessuti colici, l'aumento del c-AMP e la soppressione del TNF-α in un modello di colite murina. Questa presentazione è programmata per il 5 maggio 2025.
Palisade Bio (NASDAQ: PALI) anunció que dos resúmenes sobre su programa principal PALI-2108 para el tratamiento de la colitis ulcerosa han sido seleccionados para su presentación en la Digestive Disease Week (DDW) 2025, programada del 3 al 6 de mayo en San Diego.
La primera presentación, centrada en enfoques bioinformáticos para el tratamiento con PALI-2108 en colitis ulcerosa, explorará el potencial de eficacia antifibrótica con la inhibición local de PDE4 en la fibrosis intestinal. Esta sesión está programada para el 4 de mayo de 2025.
El segundo resumen, reconocido como Poster of Distinction y clasificado en el 10% superior de todos los resúmenes de AGA, presentará hallazgos sobre las propiedades del profármaco inibidor de PDE4 específico del colon de PALI-2108. La investigación demuestra la bioactivación del fármaco en el colon, su reducción dependiente de la dosis de PDE4B en el tejido colónico, el aumento de c-AMP y la supresión de TNF-α en un modelo de colitis en ratones. Esta presentación está programada para el 5 de mayo de 2025.
팔리세이드 바이오 (NASDAQ: PALI)는 자사의 주요 프로그램 PALI-2108이 궤양성 대장염 치료를 위해 소화기 질환 주간 (DDW) 2025에서 발표될 두 개의 초록이 선정되었다고 발표했습니다. 이 행사는 5월 3일부터 6일까지 샌디에이고에서 열릴 예정입니다.
첫 번째 발표는 궤양성 대장염에서 PALI-2108 치료를 위한 생물정보학적 접근에 중점을 두며, 장 섬유증에서 국소 PDE4 억제를 통한 항섬유화 효능 잠재력을 탐구할 것입니다. 이 세션은 2025년 5월 4일로 예정되어 있습니다.
두 번째 초록은 우수 포스터로 인정받아 모든 AGA 초록 중 상위 10%에 해당하며, PALI-2108의 대장 특이적 PDE4 억제제 프로약물의 특성을 발표할 것입니다. 연구 결과는 약물이 대장에서 생물활성화되고, 대장 조직 PDE4B가 용량 의존적으로 감소하며, c-AMP가 증가하고, 쥐의 대장염 모델에서 TNF-α 억제가 이루어짐을 보여줍니다. 이 발표는 2025년 5월 5일로 예정되어 있습니다.
Palisade Bio (NASDAQ: PALI) a annoncé que deux résumés concernant son programme principal PALI-2108 pour le traitement de la colite ulcéreuse ont été sélectionnés pour être présentés lors de la Digestive Disease Week (DDW) 2025, prévue du 3 au 6 mai à San Diego.
La première présentation, axée sur des approches bioinformatiques pour le traitement avec PALI-2108 dans la colite ulcéreuse, explorera le potentiel d'efficacité antifibrotique avec l'inhibition locale de la PDE4 dans la fibrose intestinale. Cette session est prévue pour le 4 mai 2025.
Le deuxième résumé, reconnu comme Poster of Distinction et classé dans le top 10 % de tous les résumés AGA, présentera des résultats sur les propriétés pro-médicament inibiteur de la PDE4 spécifique au colon de PALI-2108. La recherche démontre la bioactivation du médicament dans le colon, sa réduction dépendante de la dose de la PDE4B dans les tissus coliques, l'augmentation du c-AMP et la suppression du TNF-α dans un modèle de colite murine. Cette présentation est prévue pour le 5 mai 2025.
Palisade Bio (NASDAQ: PALI) hat angekündigt, dass zwei Abstracts zu seinem Hauptprogramm PALI-2108 zur Behandlung von Colitis ulcerosa für die Präsentation bei der Digestive Disease Week (DDW) 2025 ausgewählt wurden, die vom 3. bis 6. Mai in San Diego stattfinden wird.
Die erste Präsentation, die sich auf bioinformatische Ansätze zur Behandlung mit PALI-2108 bei Colitis ulcerosa konzentriert, wird das Potenzial der anti-fibrotischen Wirksamkeit durch lokale PDE4-Hemmung bei intestinaler Fibrose untersuchen. Diese Sitzung ist für den 4. Mai 2025 geplant.
Der zweite Abstract, der als Poster of Distinction anerkannt und unter den besten 10% aller AGA-Abstracts eingestuft wurde, wird Ergebnisse zu den kolonspezifischen PDE4-Inhibitor-Prodrug-Eigenschaften von PALI-2108 präsentieren. Die Forschung zeigt die Bioaktivierung des Medikaments im Colon, die dosisabhängige Reduktion von PDE4B im Kolongewebe, eine Erhöhung von c-AMP und die Unterdrückung von TNF-α in einem Mausmodell für Colitis. Diese Präsentation ist für den 5. Mai 2025 geplant.
- Abstract rated in top 10% of AGA submissions, demonstrating strong scientific recognition
- Preclinical data shows multiple positive mechanisms of action for PALI-2108
- Selection for presentation at major industry conference increases visibility
- Research still in preclinical stage with no human trial data presented
- No efficacy or safety data in human patients reported
PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top
Carlsbad, CA, March 12, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to present data from its lead program PALI-2108 for the treatment of ulcerative colitis at Digestive Disease Week® (DDW) 2025 being held May 3–6, in San Diego, California.
Participation details are as follows:
Poster Presentation
Session Title: Transcriptional, Epigenetic and Genetic Regulation of GI Function and Disease
Session Date & Time: May 4, 2025 from 12:30 PM to 1:30 PM PDT
Title: A BIOINFORMATIC APPROACH TO PALI-2108 TREATMENT IN ULCERATIVE COLITIS REVEALS THE POTENTIAL FOR ANTI-FIBROTIC EFFICACY WITH LOCAL PDE4 INHIBITION IN INTESTINAL FIBROSIS
DDW Poster of Distinction – Poster Presentation
Session Title: In Vivo Models of Gastrointestinal Disorders
Session Date & Time: May 5, 2025 from 12:30 PM to 1:30 PM PDT
Title: PALI-2108, A COLON-SPECIFIC PDE4 INHIBITOR PRODRUG, IS BIOACTIVATED IN THE COLON AND REDUCES COLON TISSUE PDE4B IN A DOSE-DEPENDENT MANNER, INCREASING C-AMP AND SUPPRESSING TNF-Α IN A MOUSE MODEL OF COLITIS
Digestive Disease Week is a leading forum for experts in the field of gastroenterology bringing together clinicians, researchers, and pharmaceutical leaders to discuss the latest advancements in treating digestive diseases. For more information about Digestive Disease Week please visit the conference website.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the Company’s Phase 1b/2a clinical study, indications and anticipated benefits of PALI-2108 and the expected timing of the release of topline data from the Phase 1b/2a clinical study. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company is heavily dependent on the success of PALI-2108, which is in the early stages of clinical development and may not successfully progress through clinical development or receive regulatory approval; preliminary clinical study results or the results from earlier preclinical studies may not be predictive of final or future results and unexpected adverse side effects or inadequate efficacy of PALI-2108 may limit its development, regulatory approval and/or commercialization; the Company needs to raise significant additional funds to support its operations and the continued development of PALI-2108; the timing and outcome of the Company’s current and anticipated clinical studies related to its product candidates; indications of use and estimates about the size and growth potential of the markets for the Company’s product candidates, and its ability to serve those markets, including any potential revenue generated; the Company’s ability to maintain the Nasdaq listing of its securities; the Company’s ability to compete effectively in a competitive industry; the Company’s ability to identify and qualify manufacturers to provide API and manufacture drug product; the Company’s ability to enter into commercial supply agreements; the Company’s ability to attract and retain key scientific or management personnel; the accuracy of the Company’s estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and the impact of any global event on the Company’s business, and operations, and supply. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
What are the key findings of PALI-2108 in the mouse colitis model presented at DDW 2025?
Why was Palisade Bio's PALI-2108 abstract selected as a Poster of Distinction at DDW 2025?
What therapeutic areas is PALI-2108 being developed for?
When and where will Palisade Bio present their PALI-2108 research at DDW 2025?
